CoChat

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy

Open access
Morano, Federica, Corallo, Salvatore, Lonardi, Sara, Raimondi, Alessandra, Cremolini, Chiara, Rimassa, Lorenza, Murialdo, Roberto, Zaniboni, Alberto, Sartore-Bianchi, Andrea, Tomasello, Gianluca, Racca, Patrizia, Clavarezza, Matteo, Adamo, Vincenzo, Perrone, Federica, Gloghini, Annunziata, Tamborini, Elena, Busico, Adele, Martinetti, Antonia, Palermo, Federica, Loupakis, Fotios, Milione, Massimo, Fucà, Giovanni, Di Bartolomeo, Maria, de Braud, Filippo, Pietrantonio, Filippo · 2019 · Journal of Clinical Oncology
Cited by 111

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

PURPOSE: We assessed the prognostic/predictive role of primary tumor sidedness and uncommon alterations of anti–epidermal growth factor receptor (EGFR) primary resistance (primary resistance in RAS and BRAF wild-type metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies [PRESSING] panel) in patients with RAS/ BRAF wild-type (wt) metastatic colorectal cancer (mCRC) who were randomly assigned to panitumumab plus fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) induction followed by maintenance with panitumumab with or without fluorouracil (FU) plus leucovorin (LV); Valentino trial (ClinicalTrials.gov identifier: NCT02476045 ). PATIENTS AND METHODS: This prespecified retrospective analysis included 199 evaluable patients with RAS/ BRAF wt. The PRESSING panel included the following: immunohistochemistry (IHC) and in situ hybridization for HER2/MET amplification, IHC with or without RNA sequencing for ALK/ROS1/NTRKs/RET fusions, next-generation sequencing for HER2/ PIK3CAex.20/PTEN/ AKT1 and RAS mutations with low mutant allele fraction, and multiplex polymerase chain reaction for microsatellite instability. PRESSING status (any positive biomarker v all negative) and sidedness were correlated with overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) in the study population and by treatment arm. RESULTS: Overall, left- and right-sided tumors were 85.4% and 14.6%, respectively, and PRESSING-negative and -positive tumors were 75.4% and 24.6%, respectively. At a median follow-up of 26 months, inferior outcomes were consistently observed in right- versus left-sided tumors for ORR (55.2% v 74.1%; P = .037), PFS (8.4 v 11.5 months; P = .026), and OS (2-year rate: 50.2% v 65.1%; P = .062). Similar results were observed in the PRESSING-positive versus PRESSING-negative subgroup for ORR (59.2% v 75.3%; P = .030), PFS (7.7 v 12.1 months; P < .001), and OS (2-year rate: 48.1% v 68.1%; P = .021). The PFS benefit of FU plus LV added to panitumumab maintenance, reported in the study, was independent from sidedness and PRESSING status (interaction for PFS P = .293 and .127, respectively). However, outcomes were extremely poor in patients who received single-agent panitumumab and had right-sided tumors (median PFS, 7.7 months; 2-year OS, 38.5%) or PRESSING-positive tumors (median PFS, 7.4 months; 2-year OS, 47.0%). CONCLUSION: The combined assessment of sidedness and molecular alterations of anti-EGFR primary resistance identified a consistent proportion of patients with RAS/ BRAF–wt mCRC who had inferior benefit from initial anti-EGFR–based regimens, particularly after maintenance with single-agent anti-EGFRs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.19.01254

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 111

Metadata

Authors
Morano, F., Corallo, S., Lonardi, S., Raimondi, A., Cremolini, C., Rimassa, L., Murialdo, R., Zaniboni, A., Sartore-Bianchi, A., Tomasello, G., Racca, P., Clavarezza, M., Adamo, V., Perrone, F., Gloghini, A., Tamborini, E., Busico, A., Martinetti, A., Palermo, F., Loupakis, F., Milione, M., Fucà, G., Di Bartolomeo, M., de Braud, F., & Pietrantonio, F.
Venue
Journal of Clinical Oncology
Published
2019-11-20
Volume
37
Issue
33
Pages
3099-3110
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2973672931
Cited by
111
References
18
FWCI
4.08
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. https://app.cochat.ai/papers/10.1200/jco.19.01254
The paper
Morano, F., Corallo, S., Lonardi, S., Raimondi, A., Cremolini, C., Rimassa, L., Murialdo, R., Zaniboni, A., Sartore-Bianchi, A., Tomasello, G., Racca, P., Clavarezza, M., Adamo, V., Perrone, F., Gloghini, A., Tamborini, E., Busico, A., Martinetti, A., Palermo, F., . . . Pietrantonio, F. (2019). Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.19.01254

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.